The Effect of Bitter Melon (Momordica charantia) Extract on the Uptake of Tc-99m Labeled Paclitaxel: In Vitro Monitoring in Breast Cancer Cells


YURT KILÇAR A. , Yildiz O., Dogan T., Sulu E., Takan G., Muftuler F. Z. B.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.20, ss.1497-1503, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 20 Konu: 12
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2174/1871520620666200424124746
  • Dergi Adı: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Sayfa Sayıları: ss.1497-1503

Özet

Background: Bitter Melon Extract (BME) is widely used for the treatment of various diseases worldwide due to its rich phytochemical and antioxidant content. The well-known anti-cancer drug Paclitaxel (PAC) plays a major role in the treatment of various cancer types such as ovarian, breast, and lung cancer. Technetium-99m ((99)mTc) radiolabeled paclitaxel is emerging as an imaging probe for breast cancer in vivo. (99)mTc labeled compounds have been attracting more scientific attention since the achievement of earlier researches in Nuclear Medicine. People consume several types of diets of plant origin without knowing the interaction with radiolabeled compounds or radiopharmaceuticals.